Navigation Links
Shire Recognized by ISPE Facility of the Year Awards Program
Date:1/24/2011

LEXINGTON, Mass., Jan. 24, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the Project Atlas manufacturing facility in Lexington, Massachusetts has been recognized with an honorable mention in the ISPE (International Society for Pharmaceutical Engineering) Facility of the Year Awards program.

Project Atlas was selected from a group of 26 state-of-the-art projects constructed in 11 different countries. The Facility of the Year Awards program recognizes pharmaceutical manufacturing projects that utilize new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing high-quality medicines.

Among the reasons given for the recognition, the judges noted Shire's extensive deployment of single-use technologies at commercial scale, and the ability to overcome challenges and make technical adaptations to implement fully single-use upstream process technology at a 2,000 liter scale. As a result, the facility was effectively built faster, with reduced investment and lower utility requirements.

"We are honored to be recognized by ISPE for our work on the Atlas Project," said Bill Ciambrone, Head of Technical Operations at Shire HGT. "In less than three years, we have successfully built, commissioned, and performed validation runs in a facility that enables us to develop therapies to treat those suffering from orphan diseases around the world. As the ISPE judges noted, Project Atlas is the embodiment of Shire's vision – which is to be as brave as the people we help."

The Atlas facility supports the manufacture of REPLAGAL® (agalsidase alfa), VPRIV® (velaglucerase alfa), and Shire's robust pipeline of future development programs.  Along with Atlas, Shire owns four buildings in Lexington that serve as the global center for Shire HGT, the business unit of Shire dedicated to the study of orphan diseases.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Shire plc: PharmaVitae Profile
2. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
3. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
4. Atrium Recognized by New Hampshire Bio/Medical Council
5. Shire Update on ProAmatine(R) (midodrine HCl)
6. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
7. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
8. Shire Purchases Strategic Site in Massachusetts
9. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
10. Area Residents Can Give a Little, Help A Lot at Shires BIG GIVE
11. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):